Press Release & Community Update: Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Industry News
Blog|Apr 7 2025
Meet the Community: Natalija Stanojevic
Community
Blog|Mar 31 2025
Meet the Community: Tyler and Amanda
Community
News|Mar 31 2025
March 2025 – Advocacy Newsletter
Advocacy
Blog|Mar 25 2025
Meet the Community: Julie Haffner
Community
News|Mar 24 2025
Press Release & Community Update: Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Industry News
News|Mar 24 2025
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Industry News
Blog|Mar 17 2025
Meet the Community: Sam Dupre
Community
News|Mar 17 2025
SKYCLARYS™ (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich’s Ataxia Treatment in Canada